Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sánchez, M. A. G.
Right arrow Articles by Torbicki, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sánchez, M. A. G.
Right arrow Articles by Torbicki, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Foreword: right ventricular function and pulmonary hypertension

Miguel Angel Gómez Sánchez1,* and Adam Torbicki2

1 Heart Failure and Pulmonary Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid, Spain
2 Department of Chest Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland

* Corresponding author. E-mail address: mangomezs@telefonica.net

The first 10% of the full text of this article appears below.

The last decade has been a period of great advances in the field of pulmonary arterial hypertension (PAH). Many randomized clinical trials have assessed the efficacy of emerging medications developed to modify the fatal course of this disease. All those clinical investigation has been devoted to improve the exercise tolerance by acting on the pulmonary arterioles.

Although PAH is a disease of pulmonary vessels, it predominantly affects . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?